

INDEX

Note: Page numbers followed by “f” and “t”
indicate figures and tables, respectively.

- A1C (glycosylated hemoglobin), 37-38, 37f. See also *Glucose control*.
 - chart of results, 38f
 - explanation of, 37-38, 37f
 - frequency of measurement, 52
 - level/value
 - comparing with DCCT, 33-35, 34f
 - controlling. See also *Glucose control*.
 - for diabetes diagnosis, 29t, 30, 30f
 - goals for, 36-37, 36t, 236, 409
 - home monitoring of, 39, 39f
 - lower, with insulin pump, 173
 - lowering with CGM, 192
 - normal level, 30, 30f
 - in prediabetes, 30, 30f, 399
 - relationship with blood glucose levels, 37, 38f
 - tight glucose control (DCCT study), 33-35, 34f
 - understanding test results, 51-52
 - as “long-term glucose-control factor,” 37-38, 37f
 - test for, 30, 30f
- A1CNow (HGM device), 39f
- Acanthosis nigricans, 320, 321f
- Acarbose (Precose), 114-115, 114t, 115t, 307, 397
 - in STOP-NIDDM study, 398t, 401
- Accu-Chek (insulin pump), 176f
- Accupril (quinapril), 245t, 266t
- ACE (angiotensin-converting enzyme) inhibitors, 245t, 246, 266t
 - cautions for some patients, 266
 - kidneys, benefits for, 259, 265-266
- Aceon (perindopril), 245t, 266t
- Acetohexamide (Dymelor), 109t
- Aciphex (rabeprazole), 299
- ACT NOW study, 398t, 400
- Actoplus Met (pioglitazone/metformin), 123t
 - XR (Actoplus Met XR), 123t
- Actos (pioglitazone), 115-117, 116t
 - ACT NOW study, 398t, 400
 - combined with metformin (Actoplus Met), 123t
 - for diabetes prevention, 397, 404
 - macular edema and, 277
- Acupuncture, 283
- Addyi (flibanserin), 342
- Adhesive capsulitis (frozen shoulder), 292
- Adlyxin (lixisenatide), 125-128, 127t
 - plus Lantus (Soliqua), 128, 129t, 155
 - side effects, 307
- Admelog (lispro U-100), 141t, 143, 144t
- Adrenalin (epinephrine), 226-227
- Adult-onset diabetes. See *Type 2 diabetes*.
- Advicor (lovastatin/niacin ER), 251t
- Advil (ibuprofen), 300

Advocacy (self-advocacy), 18, 20, 21, 38, 411
Diabetes Community Advocacy Foundation, 364, 368t
DiabetesAdvocates.org, 364, 368t
online support for, 362, 364

Afrezza, 137, 141t, 143, 143f, 144t, 145-147
as add-on therapy, 145
delivery system, 145-146
safety of, 146-147
time course of action, 141t, 145, 146

Age at onset
type 1 diabetes, 23, 25t
type 2 diabetes, 25t, 26

Air travel. See *Travel*.

Alarms
CGM device, 190, 192, 193-194, 202-204, 205, 207
alarm fatigue, 203, 204
alarm settings, 202-204, 221t
case studies, 214, 215-218
insulin pump, 184

Albiglutide (Tanzeum), 125-128, 127t, 235

Albumin, 259
in diabetic kidney disease, 259-262
in urine (microalbuminuria), 259-262

Alcohol, 66-69
“allowable” (ADA recommendations), 68
blood pressure and, 86
carbohydrates and calories in, 67-68, 67t
how to stay safe while drinking, 68
hypoglycemia and, 67, 229-230
types of alcoholic drinks, 66, 67t

Alerts
continuous glucose monitors, 190, 202-204, 221t
insulin pumps, 182-183

Aleve (naproxen), 300

Algorithms
for insulin use, 156-159, 158f
for treatment of type 2 diabetes, 132, 133f

Aliskiren (Tekturna), 245t, 246

Alogliptin (Nesina), 118, 119f, 235
combined with metformin (Kazano), 123t
combined with pioglitazone (Oseni), 123t

Alpha-blockers, 245t, 246-247

Alpha cells, 226

Alpha lipoic acid, 282

Altace (ramipril), 245t, 266t

Altacor (lovastatin), 251t, 268t

Amaryl (glimepiride), 109t, 307
exercise-induced hypoglycemia and, 98

American Association of Diabetes Educators (AADE), 422

American Diabetes Association, 419
diagnosis criteria, 29, 29t
glucose goals, 36t
testing/examination recommendations, 36t, 423

Amitriptyline, 282, 301

AmLactin, 324

Amlodipine (Norvasc), 245t
Amlodipine/atorvastatin (Caduet), 245t, 251t
Amputations. See also *Feet*.
 preventing, 279
Amylin (Symlin), 151-154, 299
Ankle edema, 117
Antacids, 299, 300
Antibiotics, 286, 301
Antidepressants, 282, 301
Antifungal medications, 300, 318-319
Antiseizure medications, 282
Apidra (glulisine), 141t, 143
 sick-day recommendations, 64
 time course of action, 141t
 tips for using, 144t
Appetite, satiety and, 124f, 125, 151
ARBs (angiotensin receptor blockers), 245t, 246, 267t
 kidneys, benefits for, 259, 267
Arteries, 283-284
Aspart (Novolog), 141t, 143, 143f, 144t
 Fiasp (faster-acting aspart), 141t, 143f, 144-145
 Ryzodeg 70/30, 142t
Aspirin, 253, 255, 300, 322, 374
Asymptomatic stage, 27, 408
Atacand (candesartan), 245t, 267t
Atenolol (Tenormin), 245t
Atherosclerosis, 237, 239, 255. See also *Heart disease*.
 family history of, 240
Athlete's foot (tinea pedis), 318-319, 318f
Atorvastatin (Lipitor), 251t, 252, 268t
 combined with amlodipine (Caduet), 245t, 251t
Atropine/diphenoxylate (Lomotil), 304
Auto accidents, 330
Autoimmune diabetes
 latent, in adults (LADA), 25-26
 type 1 diabetes, 24, 405, 406
Autoimmunity, 24, 405, 406
Autonomic neuropathy, 101
Avandamet (rosiglitazone/metformin), 123t
Avandaryl (rosiglitazone/glimepiride), 123t
Avandia (rosiglitazone), 115-117, 116t, 397
 combined with glimepiride (Avandaryl), 123t
 combined with metformin (Avandamet), 123t
 macular edema and, 277
Avapro (irbesartan), 245t, 267t
Azilsartan (Edarbi), 245t, 267t

Bacterial overgrowth syndrome, 301
Bad breath (halitosis), 312
Balance training, 96-97
Baron, Alain, 17
Basaglar (glargine), 141t, 147, 165t
Basal insulin. See *Insulin, basal; Insulin therapy, basal*.
Basal/bolus. See *Insulin therapy, basal/bolus*.
Behavioral Diabetes Institute (BDI), 46, 48, 50-51, 419
 web site, 54, 419

Beliefs, harmful, 47-48
 challenging, 50-51
Benazepril (Lotensin), 245t, 266t
Benicar (olmesartan), 245t, 267t
Beta-blockers, 245t, 247
Beta cells, 25, 41, 124f, 226, 405
Betaxolol (Kerlone), 245t
Biguanides, 108, 112-114, 113t
Bile acid sequestrants, 108, 120-121, 121t
 for abnormal cholesterol levels, 251t, 252
Biosimilars, 142t, 147
Bisoprolol (Zebeta), 245t
Blogs, 366, 368t
Blood flow problems, 283-284
Blood glucose. See also *Glucose; Glucose control*.
 carbohydrates and, 74-76
 kidney function and, 119, 136f
 records, 63
 relationship with A1C (glycosylated hemoglobin), 37, 38f
 stability in nondiabetic people, 139-140
 testing, for diabetes diagnosis, 29-31, 29t, 30f
 in type 1 diabetes (fluctuations of), 23
 in type 2 diabetes (elevation of), 27, 28f, 30
Blood glucose meters, 403, 425-426, 428t-434t
Blood pressure
 controlling, 242-243, 242t, 244-247, 245t, 264-265
 aggressive therapy, 242
 dietary measures, 86-87
 importance of, 410
 diabetes medication effects on
 SGLT-2 inhibitors, 120, 253
 thiazolidinediones (TZDs), 116
 frequency of measurement, 52
 goals for, 243, 244, 264-265, 265t, 410
 high
 diabetes associated with, 25t, 31t, 402t
 as heart disease and stroke risk factor, 241
 “white coat” phenomenon, 59
 low (hypotension), 120
 measurement of, 264, 410
 medications for, 244-247, 245t, 265-267, 266t
 ACE inhibitors, 245t, 246, 265-266, 266t
 alpha-blockers, 245t, 246-247
 ARBs, 245t, 246, 267, 267t
 beta-blockers, 245t, 247
 calcium channel blockers (CCBs), 245t, 246
 centrally acting agents, 245t, 247
 combination therapy, 244, 245t, 251t, 253
 designing a regimen for, 243-244
 direct renin inhibitor, 245t
 indoline diuretic, 245t, 247
 list of agents, 245t
 monotherapy, 244
 thiazide diuretics, 245t, 247

Blood pressure (*continued*)
 monitoring, 243, 410
 home monitoring, 410
 salt and, 86, 87

Blose, Jamie S., 107

Blumer, Ian, 55, 57f, 59, 371, 378

Blurry vision, 30

BMI (body mass index), 73-74, 75t

Body mass index (BMI), 73-74, 75t

Boland, Brigid, 297

Boluses
 carb bolus (insulin pump), 173t, 179-180
 correction bolus, 173t, 180, 181t
 insulin (basal/bolus regimen), 167-169, 170t
 insulin (normal function), 140
 insulin pumps and, 173t, 179-180

Bone fractures, 280

Bourdette, Sandy, 18

Boyle, Patrick J., 225

Brain, glucose and, 227-228

Breast cancer, 113, 344

Brittle diabetes. See *Type 1 diabetes*.

Bromocriptine (Cycloset), 121-122, 122t

Butter, 85, 87

Bydureon (extended-release exenatide), 126, 127, 127t, 235
 hypoglycemia risk and, 99
 side effects, 307

Byetta (exenatide), 126, 127t, 299, 305, 307
 extended-release (Bydureon), 126, 127, 127t
 hypoglycemia risk and, 99, 235

Caduet (amlodipine/atorvastatin), 245t, 251t

Calcium channel blockers (CCBs), 245t, 246

Calories, 71-73
 in alcoholic drinks, 67-68, 67t
 calculating, 73, 423

Calorie King (web site), 423

calories per day, 72

 1500-calorie diet, 72, 84-85

mobile apps for, 68

Canagliflozin (Invokana), 118-120, 120t, 235, 253-254
 combined with metformin XR (Invokamet/XR), 123t
 kidney health and, 264

Cancer, 89, 113, 358
 bladder, 117
 breast, 113, 344
 liver, 305
 lung, 146
 skin, 322
 thyroid, 127, 128t

Candesartan (Atacand), 245t, 267t

Candidiasis (fungal/yeast infection), 311-312

Candy, 65

Capoten (captopril), 245t, 266t

Capsaicin cream, 283

Captopril (Capoten), 245t, 266t
Carbamazepine (Tegretol), 301
Carbohydrate, 74-80, 76t, 88
 in alcoholic drinks, 67-68, 67t
 amount recommended per day, 74, 77t
 bargains, 77t, 78, 81, 88
 blood sugar and, 74
 carb bolus (insulin pump), 173t, 179-180
 counting, 74, 76-80, 155-156
 “deal or no deal” examples, 76-80
 food tips, 78, 79-80
 foods containing, 74, 76t, 77t, 78, 88
 grams of carbohydrate, 77t
 how much in one meal?, 77t
 low-carbohydrate options, 87
 portion size, 74, 79
 vegetables and, 76t, 77t, 78, 81
Carbohydrate absorption inhibitors, 108, 114-115, 114t, 397
 benefits and shortfalls, 115, 115t
 starting therapy with, 115t
Cardiovascular disease, 237-255. See also *Heart attack; Heart disease*.
 cardiovascular outcome trials (CVOTs), 240
 exercise and, 90, 102
 mortality from, 237-238, 238t, 327, 327f
 sleep apnea and, 325, 327, 327f, 337
 thiazolidinediones (TZDs) and, 116
Caregivers. See *Health care providers*.
Carmol-40 (urea), 318, 324
Carpal tunnel syndrome (CTS), 291-292
Carvedilol (Coreg), 245t, 247
Causes of diabetes
 type 1, 24, 25t, 405
 type 2, 25t, 27
Cavaiola, Tricia Santos, 237
Celiac disease (celiac sprue), 302-303
Centers for Disease Control (CDC)-Diabetes Home Page, 423
Centrally acting agents, 245t, 247
CGM. See *Continuous glucose monitoring (CGM)*.
Charcot’s joint, 280-281, 293
Cheese, 83, 84t
Cheiroarthropathy, 289-290, 290f, 295
Children with diabetes, 405, 421, 426
 CWD.com, 364
 Juvenile Diabetes Research Foundation, 366, 406, 420
Chlorothiazide (Diuril), 245t
Chlorpropamide (Diabinese). See *Diabinese*.
Cholesterol, 85-86, 248-253, 410
 abnormal levels, 248-249, 248t, 250, 410
 categories of, 250
 diabetes risk and, 31t
 heart disease risk and, 241, 248, 255
 controlling, 248-253, 248t, 251t, 268, 410
 bile acid sequestrants, 251t, 252
 cholesterol absorption inhibitor, 250-251, 251t
 combination drugs, 251t, 253

Cholesterol, controlling (*continued*)
 diet and exercise, 249-250
 goal levels, 248t, 410
 niacin or nicotinic acid, 251t, 252
 PCSK9 inhibitors, 251-252, 251t
 statins, 250-251, 251t, 268t
 thiazolidinediones (TZDs) and, 116
 egg yolk and, 85
 foods containing, 85-86
 frequency of measurement, 52, 63, 249, 410
 goal levels, 248t, 410
 high
 heart attack and, 248
 type 2 diabetes and, 25t, 31t
 monitoring, 62, 63, 249, 410
 types of
 HDL, 248-249, 249t, 250, 410
 LDL, 248-249, 249t, 250-251, 268, 410
Cholestyramine (Questran), 251t, 252
Cialis, 350
Cigarette smoking, 241
Circle diagram, 361, 361f
Cisapride (Propulsid), 299
Civil Rights, US Office for, 426
Clinical trials. See also *Prevention of diabetes*.
 on diabetes prevention, 398t, 399-401
 on tight glucose control (DCCT), 32-35, 34f
 volunteering for, 404, 405-406
Clobetasol, 321
Clonidine (Catapres), 245t
Close Concerns, 421
Clotrimazole (Lotrisone), 319
Coach (diabetes coach), 88
Cohen, Deborah, 339
Colberg, Sheri, 89
Colesevelam (Welchol), 120-121, 121t, 251t
Colestid (colestipol), 251t, 252
Colestipol (Colestid), 251t, 252
Collete Diabetes Network, 419
Coma, diabetic, 228, 234, 379. See also *Unconsciousness*.
Combination therapy, 122, 123t, 131-132, 133f, 136
 algorithm for, 133t
 for blood pressure control, 244, 245t, 251t, 253
 for cholesterol control, 251t, 253
 for glucose control, 131-132, 132t
 insulin and, 130, 163-164, 170t
Complications of diabetes, 31-36. See also *Eye disease; Kidney disease*.
 exercise and, 100-102
 glucose control and, 32-36, 34f, 36t
 macrovascular (acute or short-term), 32, 35-36, 36t, 237
 microvascular (long-term), 32-35, 36t, 258, 410
 poor glucose control and, 35-36, 36t
 preventing, 32-36, 397
 with blood pressure control, 410
 with good glucose control, 31-36, 34f, 228, 279
 reducing, 32-36, 34f, 410

Conferences, TCOYD, 18, 19, 411-412
 Constipation, 303
 Continuing education, 19-20, 415-416
 Continuous glucose monitoring (CGM), 43-44, 189-223, 409
 airplane travel and, 394
 alerts and alarms, 190, 202-204, 221t
 benefits of, 43-44, 159-161, 162t, 192-198, 409
 download data, see the big picture, 195-198
 hypoglycemia reduction, 193-195, 220
 less time in high zone, 192-193
 less time in low zone, 193-194
 lower A1C, 192
 night time hypoglycemia reduction, 194-195
 clinical scenarios, 209-220
 blood glucose levels at night, 218-220
 blood glucose on the rise, 209-214
 blood glucose on the way down, 214-218
 devices/models currently available, 191f, 205-209
 evaluating/choosing, 198-205
 models available, 191f
 pump-meter-CGM combos, 183
 fine-tuning insulin rate/dose, 195
 golden rules for, 221t-223t
 health insurance coverage of, 43, 204-205
 insulin pumps combined with, 191f
 insulin use and, 170
 lag time, 201
 limitations of, 44
 sensor inaccuracy and errors, 199-200
 “share” feature, 202
 smartphone app (Clarity), 195, 196f
 start-up period and calibrations, 200-201
 trend arrows, 190, 192f, 195-198
 trend, three views of, 198, 199f
 turnaround time, 198
 Tylenol-containing medications and, 199, 206, 223
 wearing the sensor, 200
 Continuous positive airway pressure (CPAP), 331, 332-334, 333f-335f, 333t
 Coreg (carvedilol), 245t, 247
 Corgard (nadolol), 245t
 Correction bolus (insulin pumps), 173t, 180, 181t
 Correction factor (for insulin use), 156-159, 158f
 Cortisol, 227
 Cough, 146
 Cozaar (losartan), 245t, 267t
 CPAP (continuous positive airway pressure), 331, 332-334, 333f-335f, 333t
 Crestor (rosuvastatin), 251t, 252, 268t
 Cycloset (bromocriptine), 121-122, 122t
 Cymbalta (duloxetine), 282

 Dapagliflozin (Farxiga), 118-120, 120t, 235
 combined with metformin ER (Xigduo), 123t
 DASH diet, 86
 DCCT (Diabetes Control and Complications Trial), 32-35, 34f, 228, 279
 Death rate from diabetes, 16, 35
 not a “death sentence,” 47

Degludec (Tresiba), 104, 147, 148, 150
 combined with Victoza (Xultophy), 128, 128t, 155
 initiating, 165t
 Ryzodeg 70/30, 142t
 Dehydration, 99-100
 Dentures, 314
 Desipramine, 282
 Detemir (Levemir), 141t, 143f, 147, 165t
 Dexcom G4/G5 (continuous glucose monitors), 191f, 196f, 202, 205-206
 Dexcom G5 (insulin pump), 172f, 176f
 Dexcom transmitter, Dr. Edelman wearing, 21f
 Dexilant (dexlansoprazole), 300
 DiaBeta (glyburide), 109t, 307
 exercise-induced hypoglycemia and, 98
 Diabetes
 about, 23-44
 age at onset, 23, 25t, 26
 asymptomatic stage, 27, 408
 causes of, 24, 25t, 27, 405
 circle diagram, 361, 361f
 complications of, 32-36
 definition/criteria for, 29, 29t
 diagnosis of, 29-31
 education on. See *Education*.
 emotional aspects of, 41-42, 45-54
 ethnic groups and, 25t, 26, 31t, 401
 gestational. See *Gestational diabetes*.
 history sheet, 58-59, 60f-61f
 incidence of, 24, 25t
 management of. See also *Treatment for diabetes*.
 “never too late” for, 20, 409-418
 obstacles to, 47-50
 responsibility and taking control, 18, 20, 21, 411
 numbers/levels in. See *Numbers/levels*.
 organizations related to, 419-421, 422-423, 426
 prediabetes, 29-30, 398-399
 prevention of, 397-408
 resources for, 359-369, 419-426
 risk factors for, 31t, 401-403, 402t
 screening tests, 26, 405, 408
 self-advocacy, for patients, 18, 20, 21
 symptoms of, 13, 30
 travel and, 389-396
 treatment for. See *Treatment for diabetes*.
 type 1. See *Type 1 diabetes*.
 type 2. See *Type 2 diabetes*.
 types of, 23-29, 24t
 warranty program, 55-57, 56f, 59, 410
 in the workplace, 379-388
Diabetes Burnout (Polonsky), 53
 Diabetes Control and Complications Trial (DCCT). See *DCCT*.
 Diabetes Daily, 419-420
 Diabetes Etiquette Card, 53-54
 Diabetes Forecast, 421
 Diabetes Made Visible, 364

Diabetes Mall (web site), 422
DiabetesMine.com, 362-364, 365
Diabetes Motion, 106
Diabetes Online Community (DOC), 359, 362-364, 368t
Diabetes police, 49
Diabetes Prevention Program (DPP), 398t, 399-400, 403
Diabetes Risk Test, 402
Diabetes Self-Management (web site), 421
Diabetes warranty program, 55-57, 56f, 59, 410
Diabetic Athlete's Handbook, 106
DiabeticConnect.com, 363
Diabetic dermopathy, 321, 322f
Diabetic diarrhea, 303-304
Diabetic ketoacidosis (DKA), 120
Diabetic Lawyer, 421
Diabetic nephropathy. See *Kidney disease*.
Diabetic osteoarthropathy (Charcot's joint), 280-281, 293
Diabetic retinopathy. See *Eye disease*.
Diabinese (chlorpropamide), 109t, 306
 exercise-induced hypoglycemia and, 98
Diagnosis of diabetes, 29-31, 29t, 30f
 criteria for, 29, 29t
 early, benefits of, 27, 136, 408
 tests for, 29-31, 29t, 30f
 time (years) until, 27, 28f
Diarrhea, 303-304
diaTribe, 421
Diet, 71-88, 131, 132t, 403
 action plan for changes, 80-81
 blood glucose testing and, 88
 breakfast, 76-77, 80
 butter and margarine, 85, 87
 calories in, 71-73, 423
 1500-calorie diet, 72, 84-85
 calculating calories, 73
 carbohydrates, 74-80, 76t, 77t, 81, 88
 cheese, 83, 84t
 cholesterol, 85-86
 clinical trials in, 398t, 399-400, 403
 coach (diabetes coach) for, 88
 DASH diet, 86
 eating out, 80
 eggs, 85
 fat in, 81, 82f, 83-85, 84t, 87, 88
 food journal, 73
 food labels, 73, 88
 food tips, 78, 79-81
 foods recommended for diabetics, 71
 foods that raise blood glucose most, 74-75
 frequently asked questions, 87
 gluten-free, 302-303
 grocery shopping and, 80
 leftovers, 81
 Mediterranean diet, 349, 352, 357-358, 358f
 nutrient-dense food, 71

Diet (*continued*)

- Nutrition Data (web site), 424
- nutrition teleconferences, 424
- portion sizes, 73, 74, 79, 88
- protein, 81-86, 82f, 88
 - low-protein meal plan, 267
- registered dietician, 72
- salt in, 86-87, 88
- travel and, 392-393
- vegetables, 71, 81, 88
- web sites on, 423-424
- at work, 384, 385
- Diflucan (fluconazole), 300
- Digestive tract, 297-308, 297f. See also *Gastrointestinal (GI) tract*.
- Dilantin (phenytoin), 301
- Diltiazem, 245t
- Diovan (valsartan), 245t, 267t
- Dipyridole, 322
- Direct renin inhibitor, 245t
- Disability, workplace and, 381, 385, 386, 423
- Doctor. See also *Health care providers (HCPs)*.
 - consulting before exercise, 93, 93t, 103t
 - doctor-patient relationship, 42, 61-62
 - letter for travel, 389, 390t
 - training in diabetes care, 23
- Doctor visits, 57-64
 - bringing records to, 41-42, 61, 63
 - frequency of, 57-58
 - frequency of lab tests, 63
 - honesty for, 61-62
 - list of questions for, 58t, 64
 - prescriptions, 58, 62
 - questions for, 58t, 59, 64
 - top ten tips for, 59-63
 - topics to discuss, 57-59, 58t, 64
 - what should be done at, 52, 56f, 59, 62-63
 - “white coat” phenomenon, 59
- Dr. Edelman’s Corner*, 413
- “Don’t Freak Out” (booklet), 48
- Dopamine receptor agonists, 108, 121-122, 122t
- Doxazosin (Cardura), 245t
- DPP (Diabetes Prevention Program), 398t, 399-400, 403
- DPP-4 (enzyme), 118, 125-126
- DPP-4 inhibitors (incretin enhancers), 108, 118, 119f, 125
 - as incretin enhancers, 118, 125
 - low of hypoglycemia risk, 235
- Drago, Lorena, 71
- DREAM study, 398t, 400
- Drinking. See *Alcohol*.
- Driving, motor vehicle crashes, 330, 337
- Drugs. See *Medications*.
- Dry labbing, 42, 43f
- Dry mouth (xerostomia), 311, 311t
- Duetact (pioglitazone/glimepiride), 123t
- Dulaglutide (Trulicity), 126, 127, 127t, 235
 - side effects, 307

Duloxetine (Cymbalta), 282
Duodenum, 297f
Dupuytren's contracture, 290-291
Duration of insulin action (DIA), 181-182
Dymelor (acetohexamide), 109t

E-patient movement, 359-360
Eating. See *Diet; Food*
Edarbi (azilsartan), 245t, 267t
Edelman, Steven V.
 diabetes of, 13-17
 early years, 14-16
 insulin overdose given, 14
 treatments for, 14, 16, 21t
 Dr. Edelman's Corner, 413
 The Edelman Report, 19, 411, 414
 family of, 17, 22f
 medicine, study of, 16-17
 TCOYD organization and, 18-20
Edema, 117
 macular, 274, 277
Education
 of diabetes patients, 18-19, 20-21
 be smart and persistent, 19, 21, 38
 be up-to-date, 19
 empowered patient movement, 359-360
 of health care providers, 18, 19-20, 415-416
 organizations (web sites), 422-423
 self-education, 18-19, 20-21, 411
Eggs, 85
Elavil, 301
Elderly
 falls and mental impairment in, 36, 36t
 hypoglycemia and, 235
 hypotension and, 120
Emotional aspects of diabetes, 41-42, 45-54
 obstacles to managing diabetes, 47-50
 solutions to consider, 50-54
 why is managing diabetes so tough?, 46-47
Empagliflozin (Jardiance), 118-120, 120t, 235, 253
 combined with linagliptin (Glyxambi), 123t
 combined with metformin (Synjardy), 123t
 kidney health and, 263-264
Empowered patient movement, 359-360
Enalapril (Vasotec), 245t, 266t
Environmental determinants in type 1 diabetes, 405
Epinephrine (adrenalin), 226-227
Eprosartan (Teveten), 245t, 267t
Erectile dysfunction (ED), 345-346, 349-352
 treatments, 349-352
Erythromycin, 299
Esomeprazole (Nexium), 245t
Esophagus, 298-299
 esophageal reflux, 298-299, 329-330
Estradiol cream, 345

Estrogen, 343-344
 Ethnic groups, diabetes and, 25t, 26, 31t, 401
 Etiquette: Diabetes Etiquette Card, 53-54
 Eucerin creams, 324
 Eversense (continuous glucose monitor), 207-208
 Exenatide (Byetta), 126, 127t, 235, 299, 307
 extended-release (Bydureon), 126, 127, 127t
 implantable osmotic mini-pump (ITCA 650), 130
 Exercise, 89-106, 397, 403
 aerobic, 94-95, 96
 balance training, 96-97
 benefits of, 89-91, 308
 blood glucose control and, 91-92, 94
 daily activities, 93-94, 105
 Diabetic Athlete's Handbook, 106
 doctor consult before, 93, 93t, 103t
 flexibility training, 97
 getting started, 92-93, 93t, 106
 glucose testing before and after, 161-163
 goals, 93-94, 105
 hydration for, 99-100, 101, 103t
 hypoglycemia and, 97-99, 104, 106, 111
 importance of, 89-91
 information and resources on, 106
 insulin dosage adjustment for, 104, 161-163, 163t
 low-intensity, 92-93
 motivation for, 105
 quality of life and, 90-91
 resistance training, 95-96
 risks and precautions, 97-105, 103t
 dehydration, 99-100
 diabetic complications, 100-102
 excessive fluid intake and, 99-100
 high blood pressure, 103t
 hyperglycemia, 99
 hypoglycemia, 97-99, 103t, 104, 106
 insulin use, 102-105
 oral diabetic medications and, 98-99
 orthopedic injuries and arthritis, 100
 sex as, 230
 shoes for, 103t
 time of day and, 104
 walking, 94-95, 106
 Exocrine insufficiency, 304-305
Extreme Diabetes Makeover, 19
 Eye, 271-278
 anatomy and function, 272
 bleeding into, 272-273, 274
 examination, 63, 271
 frequency of, 63, 271, 278
 new developments for, 275-276
 ophthalmologist for, 271, 278
 retina, 272
 detachment of, 102

Eye disease (diabetic retinopathy), 271-278
 about/overview, 271-274
 asymptomatic, 272
 blindness, preventing, 271, 272t, 273, 275, 278
 blood pressure control and, 410
 blood vessels
 bleeding from, 272-273, 274
 breaking, 274
 leakage from, 272-273
 blurry vision and, 30
 causes of, 276-277
 early detection and treatment, 271-272, 273
 Edelman, Steven, update on, 277-278
 exercise and, 101-102
 eye exam, frequency of, 271, 278
 forms of
 background form, 272-273, 273f
 proliferative form, 272, 273
 glucose levels and, 228, 274
 intensive glucose control, 33, 34f, 228
 laser therapy, 272, 274-275
 macular edema, 274, 277
 ophthalmologist for, 271, 278
 prevention of, 33, 34f, 228
 scar tissue, 273
 treatments for
 glucose control, tight, 274, 278
 laser therapy, 272, 274-275
 medications/drugs, 274, 276-277
 new developments, 275-276
 VEGF inhibitors, 275, 276f, 277
 vitrectomy, 273, 275
 VEGF and, 273, 275
Ezetimibe, 250-251, 251t. See also *Iytorin*; *Zetia*.

Facebook, 359, 361, 366-367, 369

Facter, Ken, 16-17

Fainting, 101

Falls, frequent in elderly, 36, 36t

Family history

 of atherosclerosis, 240

 of diabetes, 25t, 401, 402t

 of type 2 diabetes, 24, 25t, 26, 401, 402t

Famotidine (Pepcid), 299

Farxiga (dapagliflozin), 118-120, 120t, 235

Fasting blood glucose (FBG) test, 29, 29t, 30f

 prediabetes, 398

Fatigue, 13, 36t

 sleep apnea and, 325

Fats, 83-85, 84t, 88. See also *Cholesterol*.

 butter vs margarine, 85, 87

 cheese and, 83, 84t

 daily fat budget, 84t

 oils, choosing, 83, 85

 protein and, 81, 82-83, 82f

 saturated, 87, 88

FDPS (Finnish Diabetes Prevention Study), 398t, 399, 403

Feet, 279-288, 293

- blood circulation to, 283-284
- Charcot's joint, 280-281, 293
- exercise and, 100-101
- foot exam (by doctor), 63, 284
- foot inspection, daily, 285-286
- fractures, 280-281
- immunity and, 284
- neuropathy and, 279-281
 - diagnosis of, 281, 281f
 - painful diabetic (PDN), 282-283
 - treatment of, 282-283
- shoes, 103t, 392
- toenail fungus, 286, 318-319, 318f
- troubleshooting, 286
- vascular disease and, 283-284
- wounds and ulcers, 100-101, 280, 283-284, 286, 290

Felodipine (Plendil), 245t

Fena, Cyndee, 309

Fenofibrate, 251t, 252

Fiasp (faster-acting aspart), 141t, 143f, 144-145

Fiber, 74, 88, 303, 304

- fibric acid derivative medications, 251t, 252
- soluble, 74, 88
- supplements, 303, 304

Fingerstick, 41

Finnish Diabetes Prevention Study (FDPS), 398t, 399, 403

Flexibility training, 97

Flexor tenosynovitis (trigger finger), 290, 291f, 292f

Flibanserin (Addyi), 342

Fluconazole (Diflucan), 300

Fluid intake, excessive, 99-100

Fluid retention, 117

Fluvastatin (Lescol), 251t, 268t

Food, 71-88. See also *Diet*.

- food labels, 73, 88
- food trackers (online), 73
- foods recommended for diabetics, 71
- nutrient-dense, 71
- portion sizes, 73, 74, 79, 88

Foot care. See *Feet*.

Fortamet (metformin), 113t

Fosinopril (Monopril), 245t, 266t

Fractures. See *Bone fractures*.

FreeStyle Libre (continuous glucose monitor), 207

Frequency

- of doctor visits, 57-58
- of lab tests and exams, 52, 55-57, 63
 - A1C (glycosylated hemoglobin), 52
 - blood pressure, 52
 - cholesterol, 52, 63, 249, 410
 - eye exam, 271, 278
 - kidney tests, 63, 260, 269
 - record book for, 55, 56f

Frias, Juan Pablo, 397
Frozen shoulder (adhesive capsulitis), 292
Fructosamine, 38
Fruit, 71, 87
Fruit juice, 65
Fungal infections, 286, 311-312, 318-320, 318f, 319f, 320f

Gabapentin (Neurontin), 282, 301
GAD antibodies test, 25-26
Gagnon, Catherine, 339
Gallbladder, 297, 297f
Gallstones, 306
Gastric emptying, 125
Gastroesophageal reflux disease (GERD), 298-299
Gastrointestinal (GI) tract, 297-308
 anatomy/diagram of, 297f
 colon or large intestine, 303-304
 constipation, 303
 diabetic diarrhea, 303-304
 common complaints, 297, 298t
 exercise and, 308
 gallstones, 306
 liver, 304-305, 308
 microbiome, 298
 nerves, abnormal function and, 298
 pancreas, 304-305
 side effects of diabetes medications, 306-307
 small intestine, 301-303
 bacterial overgrowth syndrome, 301
 celiac disease, 302-303
 diabetic neuropathy of, 301-302
 throat and stomach, 298-300
 delayed stomach emptying, 299-300
 esophagus, 298-299
 ulcer disease, 300
 yeast infections, 300
Gastroparesis, 299-300, 307
Gemfibrozil (Lopid), 251t, 252
Genetics, diabetes and, 25t, 26, 47-48, 405
GERD (gastroesophageal reflux disease), 298-299
Gestational diabetes, 28-29, 92
 cause of, 28
 exercise and, 92
 as risk factor for type 2 diabetes, 31t, 401, 402t
 risk factors for, 29
 screening for, 30-31
 treatment of, 29
 oral medications not approved for, 108
GFR (glomerular filtration rate), 114, 262
Gila monster, 126
GIP incretin hormone, 118
Glargine, 141t, 143f
 Basaglar, 141t, 147, 165t
 combined with lixisenatide (Soliqua), 128, 129t
 Lantus, 104, 141t, 143f, 147, 165t, 398

Glargine (*continued*)
 in ORIGIN study, 398t, 401
 U-300 (Toujeo), 141t, 143f, 147, 148, 165t
 Glibenclamide (glyburide), 235
 Glimepiride (Amaryl), 109t, 307
 combined with pioglitazone (Duetact), 123t
 combined with rosiglitazone (Avandaryl), 123t
 exercise-induced hypoglycemia and, 98
 Glipizide (Glucotrol), 109t
 combined with metformin (Metaglip), 123t
 extended-release (Glucotrol XL), 109t
 hypoglycemia and, 98, 235
 Glomerular filtration rate (GFR), 114, 262
 GLP-1 (glucagonlike peptide-1), 118, 124-130, 124f
 actions of, 124-125, 124f
 deactivation of, 126
 low hypoglycemia risk, 235
 mimetics (incretin mimetics), 125-129, 127t
 receptor agonists (GLP-1 RAs), 126-128, 127t, 136, 307. See also *Byetta (exenatide)*.
 agents
 Byetta (exenatide), 126, 127t
 once-daily (Victoza, Adlyxin), 126-127, 127t
 once-weekly (Bydureon, Trulicity, Tanzeum, Semaglutide), 126-127, 127t
 benefits and shortfalls, 128t
 combination formulations (Soliqua, Xultophy), 128-129, 129t
 GLP-1 analogues, 154-155
 Glu (T1D online social network), 420
 Glucagon, 124, 124f, 151, 226
 GLP-1 and, 124, 124f
 inhibition, with incretin hormones, 118
 injection, for hypoglycemia, 231
 nasal, 231
 Glucophage (metformin), 112-114, 113t, 397. See also *Metformin*.
 for diabetes prevention, 399-400, 404
 in DPP study, 398t, 399-400
 extended-release (Glucophage XR), 112, 113t
 side effects of, 307
 Glucose. See also *Blood glucose; Glucose control*.
 control. See *Glucose control*.
 glucose-lowering medications, 107-136
 levels. See also *A1C*.
 carbohydrate impact on, 74
 controlling. See *Glucose control*.
 diabetes diagnosis, testing for, 29-31, 29t, 30f
 glucagon and, 226
 goal for, 36-37, 36t
 hypoglycemia and, 65-66
 monitoring. See *Glucose monitoring*.
 postmeal (postprandial), 30, 30f, 36t
 logbook, 63
 meters, 425-426, 428t-434t
 units of measurement (in US and abroad), 390-391
 Glucose control, 31-36, 409. See also *Glucose-lowering medications*.
 benefits of, 31-36
 combination of therapies for, 131-132, 132t

Glucose control (*continued*)

- complications, preventing with, 32-36
 - exercise and, 91-92, 94
 - goal level for, 36-37, 36t, 52-53
 - importance of, 27, 31-36, 409
 - DCCT study and, 32-35, 34f
 - insulin and. See *Insulin therapy*.
 - intensive (tight)
 - benefit of, 32-36
 - in DCCT study, 32-35, 34f, 228
 - hypoglycemia risk and, 226, 227-228, 236
 - quality of life and, 35
 - reduction in complications, 32-36
 - long-term glucose-control factors
 - A1C (glycosylated hemoglobin), 37-38, 37f
 - fructosamine, 38
 - medications for. See *Glucose-lowering medications*.
 - quality of life and, 35
- Glucose-lowering medications for type 2 diabetes, 107-136. See also *specific medications and classes of medication*.
- case presentations, 133-135
 - choice of, 107, 130-132, 132t
 - diabetes prevention and, 397-398
 - FDA guidelines on, 130
 - general guidelines for, 130-132, 132t
 - incretin mimetics, 123-130, 127t
 - GLP-1 receptor agonists (GLP-1 RAs), 126-128, 127t, 307
 - monotherapy (case), 133-134
 - oral medications, 107, 108-122
 - adding to insulin, 133f, 135, 136
 - biguanides (metformin), 108, 112-114, 113t
 - bile acid sequestrants, 108, 120-121, 121t
 - carbohydrate absorption inhibitors, 108, 114-115, 114t
 - combination medications, 122, 123t, 130
 - combination of medications, 133f, 134-135, 136
 - dopamine receptor agonists, 108, 121-122, 122t
 - DPP-4 inhibitors (incretin enhancers), 108, 118, 119f, 125
 - hypoglycemia risk increased by some, 98-99, 235
 - insulin sensitizers (thiazolidinediones), 108, 115-117, 116t
 - non-sulfonylurea insulin secretagogues, 108, 111-112, 112t
 - SGLT-2 inhibitors, 108, 118-120, 120t
 - sulfonylureas (SFUs), 108-111, 109t
 - treatment algorithm, 132, 133f
- Glucose meters, 403, 425-426, 428t-434t
- continuous glucose monitoring, 189-223
- Glucose monitoring. See *Continuous glucose monitoring; Glucose meters; Home glucose monitoring*.
- Glucotrol (glipizide), 109t
- extended-release (Glucotrol XL), 109t
 - hypoglycemia and, 98, 235
- Glucovance (glyburide/metformin), 123t
- Glulisine (Apidra), 141t, 143, 144t
- Glumetza (metformin), 113t
- Glutamic acid decarboxylase (GAD) antibodies test, 25-26
- Gluten intolerance (celiac disease), 302-303

Glyburide, 109t, 307
 combined with metformin (Glucovance), 123t
 exercise-induced hypoglycemia and, 98
 Glibenclamide, 235
 hypoglycemia risk and, 235
 Glycemic control. See *Glucose control*.
 Glycogen, 105
 GlycoMark, 38
 Glycosylated hemoglobin. See *A1C*.
 Glynase PresTab (glyburide), 109t
 Glyset (miglitol), 114-115, 114t, 115t, 397
 side effects of, 307
 Glyxambi (Linagliptin/empagliflozin), 123t
 Goldstein, Irwin and Sue, 339
 Grains, 71, 87
 Granuloma annulare, 320-321
 Guanabenz (Wytensin), 245t
 Guanfacine (Tenex), 245t
 Guzman, Susan J., 45

Halitosis (bad breath), 312
 Halpern, Kriss, 421
 Hands, 289-292
 carpal tunnel syndrome, 291-292
 diabetic cheiroarthropathy, 289-290, 290f, 295
 Dupuytren's contracture, 290-291
 flexor tenosynovitis (trigger finger), 290, 291f, 292f
 surgery for, 295, 295f
 limited joint mobility syndrome, 289-290, 290f, 295
 "prayer sign," 289, 290f
 shoulder-hand syndrome, 292-293
 Hartzell, Rose, 339
 HCPs. See *Health care providers*.
 HDL (high-density lipoprotein), 248-249, 249t, 250
 Health care providers (HCPs). See also *Doctor; Doctor visits*.
 doctor-patient relationship, 42
 education of, 18, 19-20, 415-416
 Making the Connection programs for, 19-20, 415-416
 training in diabetes (as percentage of time), 23
 Health fairs (TCOYD), 411-412
 Heart attack, 237-255. See also *Heart disease*.
 age and gender in, 240
 aspirin and, 253, 255
 cardiovascular outcome trials (CVOTs), 240
 case presentation, 254-255
 cholesterol levels and, 241, 255
 controlling, 248-252, 248t
 deaths from, 237-238, 238t
 glucose control and, 228
 high blood pressure and, 241, 242-243, 242t
 controlling, 242, 242t, 244-247, 245t
 risk factors for, 239-241, 239t, 255
 Heart disease. See also *Blood pressure; Heart attack*.
 aspirin therapy, 253, 255
 cholesterol levels, controlling, 248-252, 248t

Heart disease (*continued*)

- diabetes as risk factor for, 25t, 239
 - diabetes medications that can help reduce risk, 119, 253-254
 - exercise and, 90, 102
 - family history of, 240
 - high blood pressure and, 241, 242-243, 242t
 - controlling, 242, 242t, 244-247, 245t
 - as risk factor for stroke, 239
 - risk factors for, 238t, 239-241
 - SGLT-2 inhibitors and, 119, 253
 - thiazolidinediones (TZDs) and, 116, 117
 - warning signs, diabetes may diminish, 238
 - women's advantage with, 237-238, 238f
- Heartburn (gastroesophageal reflux), 298-299
- Helicobacter pylori*, 300
- Hemoglobin, glycosylated. See *A1C*.
- Henry, Robert, 17, 132
- Herbs, 353-354, 376-377
- Heritability
 - type 1 diabetes and, 24
 - type 2 diabetes and, 24, 26, 31t, 47-48
- High blood pressure. See *Blood pressure, high*.
- High-density lipoprotein. See *HDL*.
- History. See also *Family history*.
 - diabetes history sheet, 58-59, 60f-61f
 - natural history of type 2 diabetes, 27, 28f, 131, 138
- Home glucose monitoring (HGM), 39-43, 189
 - asking for a device, 41
 - availability of, 39
 - benefits of, 39-40, 43
 - continuous. See *Continuous glucose monitoring*.
 - devices for, 39, 39f
 - glucose meters, 425-426, 428t-434t
 - glycosylated hemoglobin (A1C) values and, 38, 38f
 - importance of, 159-161, 162t
 - insulin use adjustments and, 170
 - limitations of, 189
 - recommended for *all* diabetics, 39-40
- Hormones
 - amylin (Symlin), 151-154
 - estrogen/progesterone, 343-345
 - GIP, 118
 - GLP-1, 118, 124-130
 - incretin, 118, 123-129
 - insulin. See *Insulin*.
 - testosterone, 342-343
- Hoskins, Mike, 364
- Humalog, 141t, 143, 143f
 - sick-day recommendations, 64
 - time course of action, 141t, 143f
 - tips for using, 144t
 - U-500, 141t, 150
- Humalog Mix 75/25, and 50/50, 141t, 164
- Humulin 70/30, and 50/50, 141t
- Hydrochlorothiazide (Esidrix), 245t

Hyperglycemia, 29t, 36
 in elderly, 36, 36t
 exercise and, 99
 nocturnal, 218-220

Hypoglycemia, 65-66, 225-236
 about, 225-228
 adrenalin and, 226-227
 alcohol and, 67, 229-230
 always carry something sweet, 65-66, 139
 blood sugar and, 65-66
 brain's need for glucose and, 227-228
 case studies, 233-235
 common themes in types 1 and 2 diabetes, 225-228
 continuous glucose monitoring and, 194-195, 220
 cortisol and, 227
 exercise and, 97-99, 103t, 104, 106, 111
 glucagon and, 226
 glucagon injection, 231, 232
 glucose control and, 35, 226, 227-228, 236
 “hypoglycemia begets hypoglycemia,” 229
 hypoglycemia unawareness, 173, 220, 232-233
 “I feel fine” factor, can't depend on, 228
 insulin use and, 98, 138-139, 149
 insulin pumps/smart pumps, 232
 medications and, 98-99, 235
 insulin secretagogues, 112
 sulfonylureas, 98, 111, 226
 nighttime/nocturnal, 173, 194-195
 physiological processes of, 225-227
 preventing, 139, 228-229, 236
 sex and, 230
 symptoms of, 111
 treatment of, 65-66, 97-98, 111, 230-231
 candy, foods, and juice for, 65-66, 111, 228-229, 230-231
 glucagon injection, 231, 232
 milk for, 231
 testing blood glucose level before, 111
 type 1 diabetes and, 225, 228-234
 common themes with type 2, 225-228
 type 2 diabetes and, 225-226, 234-236
 common themes with type 1, 225-228
 oral medications for, 235
 unconsciousness from, 65, 227
 losing consciousness, 232
 weight loss and, 127

Ibuprofen, 300

IDDM (insulin-dependent diabetes mellitus). See *Type 1 diabetes*.

IFG (impaired fasting glucose), 29, 29t, 30f, 398

IGT (impaired glucose tolerance), 30, 30f, 399

Imipramine, 282

Immunity/immune system, 284, 309, 317, 405
 skin and, 317-318
 type 1 diabetes and, 405

Impaired fasting glucose (IFG), 29, 29t, 30f, 398

Impaired glucose tolerance (IGT), 30, 30f, 399

Incretin
enhancers (DPP-4 inhibitors), 118, 119f, 125
hormones, 118, 123-129
 FDA guidelines on, 130
 GLP-1, 124-130, 124f
 side effects of, 307
mimetics, 123-130, 125-129, 127t, 398. See also *GLP-1*.
 benefits and shortfalls of, 127-128, 128t
 in development, 130
 GLP-1 pens, 129f
 GLP-1 receptor agonists, 126-128, 127t, 307
 implantable osmotic mini-pump, 130
 specific agents, 127t
 stomach emptying and, 299, 307

Indapamide (Lozol), 245t

Inderal/Inderal LA (propranolol), 245t

Individualization of treatment, 31

Indoline diuretic, 245t, 247

Infection
fungal, 286, 311-312, 318-320, 318f, 319f, 320f
immune system and, 317
opportunistic, 317
oral infections, 311-312
of urinary tract, 30
yeast infections, 300, 319-320, 320f

Inhaled insulin, 141t, 143f, 145-147

Insulin. See also *Insulin therapy*.
basal (throughout the day), 140, 148
bolus (at mealtimes), 140
insulin deficiency, relative, 108
insulin resistance, 27, 28f, 108-109
normal functions of, 24, 41, 139-140, 225
normal production by pancreas, 24, 124, 124f, 139-140
secretagogues, 108-112, 112t
sensitizers, 108, 115-117, 116t
time course of action, 140-142, 143f
in type 1 diabetes (lack of), 24
in type 2 diabetes (insulin resistance), 27, 108-109

Insulin-dependent diabetes mellitus (IDDM). See *Type 1 diabetes*.

Insulin resistance, 27, 28f, 108-109
weight and, 402t

Insulin therapy, 137-170. See also *specific insulin preparations by name*.
adjunct for (Symlin, amylin), 151-154
administration of, non-physiologic nature of, 44, 142, 144
agents, 141t-142t. See also *specific agents by name*.
algorithms and sliding scales, 156-159, 158f
basal, 140, 147-149, 163-164, 165t
 agents by name, 141t
 initiating and titrating, 165t
 insulin pump and, 173t
 from insulin pumps, 173t, 177-178
 long-acting, 147-149
 meals and, 140
 normal, in nondiabetic people, 140

Insulin therapy, basal (*continued*)

- plus GLP-1 RA injectable (and pens), 128-129, 129f
- testing if dose is working, 148-149
- time course of action, 141t, 143f, 147
- vs mealtime insulins, 149
- when traveling, 395-396

 basal/bolus, 140, 167-169, 170t

- for type 1 diabetes, 140
- when traveling, 395, 396

 benefits of, 138-139

- biphasic: fixed mixtures, 141t-142t, 149-150

 bolus, 140

- case presentations, 164-170
 - combination therapy, 163-164
 - daytime oral agent and predinner premixed insulin, 164-165, 166t
 - insulin pump therapy, 169-170
 - split-mixed/premixed regimen, 166-167, 170t
 - type 1 diabetes, 168-170
 - type 2 diabetes, 165-168
- catch up, 156-159
- combination preparations (fixed mixtures), 141t-142t, 149-150, 164-165, 166t
- in combination with other medications, 130, 163-164, 170t
- continuous glucose monitoring and, 159-161, 162t, 170
- correction factors, 156-159, 158f
- dosage, 155-156, 170
 - adjusting during travel, 393, 394-396
 - adjusting for exercise, 104, 161-163, 163t
 - algorithms for, 156-159, 158f
 - correction factors, 155, 156-159, 158f
 - 1800 rule, 158-159
 - “guesstimating,” 155-156, 170
 - insulin pumps and, 173
 - time zones during travel, 394-396
 - units, 14, 390
- exercise and, 98, 102-105
- fast-acting, 141t, 143-144
 - Fiasp (faster-acting aspart), 141t, 143f, 144-145
 - time course of action, 141t, 143f
 - tips for using, 144t
- frequency of doctor visits, 57
- home glucose monitoring and, 159-161, 162t, 170
- hypoglycemia and, 98, 138-139
- inhaled insulin (Afrezza), 141t, 143, 145-147
 - time course of action, 141t, 143f
- injections, fears and misconceptions about, 138-139
- insulin menu, 156, 157t
- intermediate-acting, 141t, 143f, 149-150. See also *NPH*.
- long-acting, 147-149
- mealtime, 141t, 142-144, 149, 170
 - basal/prandial regimen, 167-169
 - case presentations, 164-165, 166t, 167-168
- needles and, 138-139
- NPH*, 141t, 143f, 149-150
- peak action, 140-142, 141t-142t, 143f, 144
- pens, 129f, 150, 159, 160f

Insulin therapy (*continued*)

- premixed, 141t-142t, 149-150, 164-165, 166t, 170t
- pumps, 171-187
 - accuracy of, 172
 - airplane travel and, 393, 394
 - backup for travel, 389, 391
 - basal insulin/rates, 173t, 177-178
 - benefits of, 172-174
 - bolus(es), 173t, 179-180, 183
 - bolus calculator, 178-179
 - bolus onboard (BOB), 182
 - carb bolus, 173t, 179-180
 - case presentation, 169-170
 - choices/models of, 174-177, 174f, 176f, 183-185
 - correction bolus, 173t, 180, 181t
 - drawbacks of, 185
 - duration of insulin action, 181-182
 - features of, 171-172, 177-183
 - glucose target, 181, 181t
 - infusion sets, 174f, 184-185
 - patch pumps, 174f, 175-177, 177f
 - pump-meter-CGM combos, 183
 - reminders and alerts, 182-183
 - temperature variables for, 392
 - travel issues, 391, 392, 393, 394
 - trend lines, 172
- rapid-acting, 141t, 143
 - sick-day rules, 64
 - time course of action, 141t, 143f
 - tips for using, 144t
- regimens, 170t
 - basal/bolus or basal/prandial, 167-169, 170t
 - combination therapy, 130, 163-164, 170t
 - insulin pump, 170t
 - split-mixed/premixed, 150, 166-167, 170t
- regular, 141t, 144
 - time course of action, 141t, 143f, 144
- resistance to, 138-139
- sensitivity factor. See *Correction factor*:
- sick-day rules, 64
- temperature variables for insulin supplies, 391-392
- time course of action of, 140-142, 141t-142t, 143f
- timing of initiation of therapy, 107, 132
- travel precautions and tips, 391-392, 393
 - adjusting insulin therapy, 394-396
 - time zones, 394-396
- types of, 142-150
 - for type 1 diabetes patients, 140, 168-170, 170t
 - for type 2 diabetes patients, 140, 165-168, 170t
- U-100 lispro (Admelog), 141t, 143, 144t
- U-200 lispro, 141t, 150
- U-300 glargine (Toujeo), 141t, 143f, 147, 148, 165t
- U-500 (Humalog), 141t, 150
- ultra-rapid-acting (inhaled insulin, Afrezza), 137, 141t, 143, 143f, 144t, 145-147
- units (in US and abroad), 390
 - necessity of having written out, 14

International Diabetes Center (IDC), 423
International Diabetes Federation (IDF), 423
Internet, 359-369, 419-426
 advocacy and, 362
 blogs, 366, 368t
 Diabetes Online Community (DOC), 359, 362-364, 368t
 empowered patient movement, 359-360
 Facebook, Twitter, Instagram, Tumblr, 359, 361, 366-367, 369
 Twitter hashtags, 367t
 highly recommended web sites, 368t
 how to start connecting, 366-367
 patient voices, 364-366
 social media, 359, 360-362, 366-367, 414
Invokamet/XR (canagliflozin/metformin XR), 123t
Invokana (canagliflozin), 118-120, 120t, 235, 253-254
 combined with metformin XR (Invokamet/XR), 123t
 kidney health and, 264
Irbesartan (Avapro), 245t, 267t
Isophane (NPH), 141t, 143f, 149-150
Isradipine (DynaCirc), 245t
Itchy skin, 323-324

Jackson, Richard, 52
Janumet (sitagliptin/metformin), 123t
Januvia (sitagliptin), 118, 119f
 combined with metformin (Janumet), 123t
Jardiance (empagliflozin), 118-120, 120t, 235, 253
 combined with linagliptin (Glyxambi), 123t
 combined with metformin (Synjardy), 123t
 kidney health and, 263-264
JDRF (Juvenile Diabetes Research Foundation), 366, 406, 420
Jentaduo (linagliptin/metformin), 123t
Job Accommodation Network (JAN), 423
Joints. See also *Musculoskeletal system*.
 Charcot's joint, 280-281, 293
 exercise and, 100
 limited joint mobility syndrome, 289-290, 290f, 295
Joslin Diabetes Clinic (Boston), 17, 50, 52
Jovanovic, Lois, 29
Juice, 65, 230
Juvenile Diabetes Research Foundation (JDRF), 366, 406, 420
Juvenile-onset diabetes. See *Type 1 diabetes*.

Kazano (alogliptin/metformin), 123t
Ketoacidosis, diabetic (DKA), 120
Ketoconazole, 319
Ketones, 64-65, 99
Khoury, Maysoun S., 309
Kidney, 257-269
 eGFR (estimated glomerular filtration rate), 114, 262
 function, 258
 blood glucose and, 119, 136t, 258
 keeping records of, 114
 metformin and, 113-114
 testing, 259-262

Kidney (*continued*)

- lab tests, frequency of, 63, 260, 269
- renal artery stenosis, 266
- SGLT-2 inhibitors and, 119, 120
- Kidney disease (diabetic nephropathy), 257-269
 - about, 258
 - aggressive treatment of, 259, 263-268, 263t, 269
 - blood pressure and, 258, 269, 410
 - screening, 262-263
 - treatment, 259, 264-267
 - case presentation, 268-269
 - cause of, 258
 - definition of, 258
 - early detection, importance of, 259, 260, 269
 - exercise and, 102
 - glucose control, tight, 33, 228, 259, 269
 - glucose levels as cause of, 258
 - as microvascular complication, 32, 258
 - prevention of, 228, 257, 259, 269
 - screening and tests, 258, 259-262
 - eGFR (estimated glomerular filtration rate), 262, 269
 - frequency of, 260, 269
 - Micral test strips, 261
 - microalbuminuria, 259-262, 260t, 269
 - urinary albumin-to-creatinine ratio (UACR), 260-261
- treatment and management, 258, 263-269, 263t
 - ACE inhibitors, 265-266, 266t, 269
 - ARBs, 267, 267t, 269
 - blood pressure control, 264-265, 269
 - cholesterol reduction, 268, 268t
 - diabetes medications, 263-264
 - glucose control, 263, 269
 - low-protein meal plan, 267, 269
- Kim, Rachel Peterson, 289
- Kombiglyze XR (saxagliptin/metformin XR), 123t
- Kruse, Ingrid, 17, 279

Lab results. See *Tests, results*.

- Lactic acidosis, 114
- LADA (Latent Autoimmune Diabetes in Adults), 25-26
- Lantus (glargine), 104, 141t, 147, 398
 - combined with Adlyxin (Soliqua), 128, 129t, 155
 - initiating, 165t
 - in ORIGIN study, 398t, 401
 - time course of action, 141t, 143f
- Large intestine, 303-304
- Latent Autoimmune Diabetes in Adults (LADA), 25-26
- Laxatives, 303
- LDL (low-density lipoprotein), 248-249, 249t, 250-251, 268
- Legal expert (web site), 421
- Legal issues in the workplace, 386
- Lescol (fluvastatin), 251t, 268t
- Levemir (detemir), 104, 141t, 147
 - cautions for, 147
 - initiating, 165t
 - time course of action, 141t, 143f

Levitra, 350
Libre Pro (continuous glucose monitor), 207
Lidocaine patch, 283
Life expectancy, exercise and, 90
Lifestyle modifications, 131, 133f, 397. See also *Diet*; *Exercise*.
 clinical studies on, 399
Limited joint mobility syndrome, 289-290, 290f, 295
Linagliptin (Tradjenta), 118, 119f
 combined with empagliflozin (Glyxambi), 123t
 combined with metformin (Jentadueto), 123t
Lipids, 248-249, 248t. See also *Cholesterol*.
 lipid panel (testing), 249
 treating abnormal levels of, 249-253, 251t
Lipitor (atorvastatin), 251t, 252, 268t
Liraglutide (Victoza), 126, 127t, 299
 combined with insulin degludec (Xultophy), 128, 128t, 155
 heart benefits of, 254
 low hypoglycemia risk, 235
 side effects, 307
Lisinopril, 245t, 266t
Lispro, 141t, 143, 143f. See also *Humalog*.
 time course of action, 141t, 143f
 U-100 (Admelog), 141t, 143, 144t
 U-500 (Humalog), 141t, 150
Livalo (pitavastatin), 268t
Liver, 297, 297f, 304-305
 fatty liver, 305-306
 exercise and, 308
 glucose production by, 225
 glucose release from, 226
 insulin action on, 225
Lixisenatide (Adlyxin), 125-128, 127t
 plus Lantus (Soliqua), 128, 129t, 155
 side effects, 307
Logbooks, 55-57, 56f, 63. See also *Record keeping*.
 dry labbing, 42, 43f
 “forgetting” to bring to doctor visit, 41-42
Lomotil (diphenoxylate/atropine), 304
Lopid (gemfibrozil), 252
Lopressor (metoprolol), 245t
Losartan (Cozaar), 245t, 267t
Lotensin (benazepril), 245t, 266t
Lotrimin Ultra, 318
Lovastatin, 251t, 268t
Low-density lipoprotein. See *LDL*.
Lyrica (pregabalin), 282, 301

Macrovascular complications of diabetes, 32, 35-36, 36t, 237
Macular edema, 274, 277
Making the Connection programs, 19-20
Management of diabetes. See also *Treatment for diabetes*.
 cornerstones of, 131-132, 132t, 409
 diet, 71-88
 glucose-lowering medications, 107-136
 need to know about advances in, 107-108

Management of diabetes (*continued*)

- “never too late” philosophy, 20, 409-418
- obstacles to, 47-50
- responsibility and taking control, 18, 20, 21, 411
- self-management plan, 52-53
- taking control of, 18-20, 411-416
- Mandibular advancement device, 334-336, 336f
- Mandibular osteotomy, 336, 337f
- Margarine, 85
- Mavik (trandolapril), 245t, 266t
- McDonald-Blumer, Heather, 289
- Meat, 81-83, 82f, 267
- Medic Alert bracelet or necklace, 103t
- Medical history, 58-59, 60f-61f
- Medications, 107-136, 371-378. See also *Glucose-lowering medications; Oral agents for type 2 diabetes.*
 - allergies/intolerance to, 376
 - can’t afford, 49
 - diabetes prevention and, 397-398
 - general guidelines for, 130-132, 132t
 - glucose-lowering, for type 2 diabetics, 107-136
 - herbal remedies and, 376-377
 - how long to stay on, 377
 - how to determine if it is working, 374
 - keeping track (records) of, 371-372
 - know why you are being treated, 373-374
 - manufacturers/company web sites, 424
 - “off-label” use of, 130, 343
 - remembering to take, 377
 - safe and effective use of, 371-378
 - sick-day rules, 64-65
 - side effects of, 306-307, 375. See also *specific medications.*
 - swallowing pills, 377
 - taking to doctor visit, 372-373
 - what to tell your doctor, 376-377
 - what to tell your pharmacist, 377-378
- Mediterranean Diet, 349, 352, 357-358, 358f
- Medline Plus, 426
- Medtronic CGM systems, 206-207, 208
- Mendoza, Rick, 422
- Metabolic syndrome, 305
- Metaglip (glipizide/metformin), 123t
- Meters (glucose meters), 425-426, 428t-434t
- Metformin, 112-114, 113t
 - agents
 - Fortamet, 113t
 - Glucophage, 112-114, 113t, 397
 - Glumetza, 113t
 - Riomet (liquid), 113t
 - benefits and shortfalls of, 112-113, 113t
 - in combination with
 - alogliptin (Kazano), 123t
 - canagliflozin (Invokamet/XR), 123t
 - dapagliflozin (Xigduo), 123t
 - empagliflozin (Synjardy), 123t

Metformin, in combination with (*continued*)

- glipizide (Metaglip), 123t
- glyburide (Glucovance), 123t
- linagliptin (Jentadueto), 123t
- pioglitazone (Actoplus Met, Actoplus Met XR), 123t
- repaglinide (Prandimet), 123t
- rosiglitazone (Avandamet), 123t
- saxagliptin (Kombiglyze XR), 123t
- sitagliptin (Janumet), 123t
- diabetes prevention and, 399-400, 404
- in DPP study, 398t, 399-400
- for gestational diabetes, 29
- hypoglycemia risk with, 235
- kidney function and, 113-114
- side effects, 307

Methyclothiazide (Enduron), 245t

Methyldopa (Aldomet), 245t

Metoclopramide (Reglan), 299

Metoprolol, 245t

Mevacor (lovastatin), 251t, 268t

Micardis (telmisartan), 245t, 267t

Micral test strips, 261

Microalbuminuria, 259-262

- blood pressure goals for, 265, 265t
- testing for, 260-262, 260t

Micronase (glyburide), 109t, 307

- hypoglycemia and, 98, 235

Microvascular diabetes complications, 32-35, 34f, 258, 410. See also *Neuropathy*.

- diabetic nephropathy (kidney disease), 257-269
- diabetic retinopathy (eye disease), 271-278
- reduced or prevented with glucose control, 32-35, 34f

Miglitol (Glyset), 114-115, 114t, 115t, 307, 397

Milk, 231

MiniMed 530G/630G/670G (insulin pumps), 176f

- with CGM, 191f

Miyares, Urban, 379, 388

Moexipril (Univasc), 245t, 266t

Monopril (fosinopril), 245t, 266t

Morse, Aaron B., 325

Motivation, 20, 105

Motor vehicle crashes, 330, 337

Motrin (ibuprofen), 300

Mouth. See also *Teeth and gums*.

- dry mouth, 311, 311t
- oral hygiene, 313-315, 313t, 316

Mouthwashes, 314

Muscle, 293-294

- cells, physical activity and, 91
- diabetic muscle infarction, 293-294

Musculoskeletal system, 289-295. See also *specific areas, e.g., hands*.

- case presentation, 295
- diabetes impact on, 289-295
- general involvement
- osteoarthritis, 294
- osteoporosis, 294

Musculoskeletal system (*continued*)

- hands, 289-292
 - muscles, 293-294
 - shoulders, 292-293
- MyDiabetesHome.com*, 421-422

- Nadolol (Corgard), 245t
- NASH (nonalcoholic steatohepatitis), 305
- Nassar, Adrienne, 389, 396
- Nateglinide (Starlix), 111-112, 112t, 397-398
- National Diabetes Education Initiative (NDEI), 423
- National Diabetes Education Program (NDEP), 423, 426
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 422, 426
- National Institutes of Health, 274, 399
- Natriuretic peptide, 329
- Natural history of type 2 diabetes, 27, 28f, 131, 138
- Nausea, 306-307
- NAVIGATOR study, 401
- NDEP (National Diabetes Education Program), 423, 426
- Necrobiosis lipoidica diabetorum (NLD), 321-322, 323f
- Needles, for insulin therapy, 138-139
- Neosporin, 286
- Nephropathy, 257-269. See also *Kidney disease*.
- Nesina (alogliptin), 118, 119f, 235
- Networking. See *Internet*.
- Neurontin (gabapentin), 282, 301
- Neuropathy, 279-281
 - autonomic, 101
 - DCCT study and, 33
 - diagnosis of, 281, 281f
 - oral, 312
 - painful diabetic neuropathy (PDN), 282-283
 - peripheral. See *Peripheral neuropathy*.
 - prevention with glycemic control, 279
 - of small intestine, 301-302
 - treatment of, 282-283
- Never too late philosophy, 20, 91, 409-418
- Niacin (nicotinic acid), 251t, 252
 - extended-release (Niaspan), 251t
- Niaspan (extended-release niacin), 251t
- Nicardipine (Cardene), 245t
- NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases), 422, 426
- NIDDM (non-insulin-dependent diabetes mellitus). See *Type 2 diabetes*.
- Nifedipine (Adalat), 245t
- Night time
 - hyperglycemia, 218-220
 - hypoglycemia, 173, 194-195
 - urination (nocturia), 329-330
- Nimodipine (Nimotop), 245t
- Nisoldipine (Sular), 245t
- Nocturia (night-time urinating), 329-330
- Non-sulfonylurea insulin secretagogues, 108, 111-112, 112t
- Nonalcoholic steatohepatitis (NASH), 305
- Non-insulin-dependent diabetes mellitus (NIDDM). See *Type 2 diabetes*.
- Novolin 70/30, 141t

Novolog (aspart), 141t, 143
 Fiasp (faster-acting aspart), 141t, 143f, 144-145
 sick-day recommendations, 64
 time course of action, 141t, 143f
 tips for using, 144t

Novolog Mixture 70/30, 50/50, 141t, 164

NPH (isophane), 141t, 149-150
 time course of action, 141t, 143f

Numbers/levels
 for diabetes diagnosis, 29-31, 29t, 30f
 fasting blood glucose (FBG), 29, 29t, 30f, 398
 goal levels
 A1C, 36-37, 36t
 blood pressure, 243, 244, 264-265, 265t, 410
 cholesterol, 248t, 410
 glucose control, 36-37, 36t
 impaired glucose tolerance (IGT), 30, 30f, 399
 need to know, 38, 51-52, 62
 oral glucose tolerance test (OGTT), 30-31, 30f
 prediabetes, 29-30, 30f, 398-399
 release-of-information form to get lab results, 39

Nutrition. *See* Diet

Nuts, 87

Obesity, 75t, 308, 402t. *See also Weight.*
 central, 31t, 402t
 childhood, 330
 diabetes and, 31t
 heart attack and, 241
 sleep apnea and, 325, 328, 328t

Obstructive sleep apnea. *See Sleep.*

Octreotide (Sandostatin), 304

“Off-label” use of medications, 130, 343

OGTT (glucose tolerance test), 30-31, 30f, 399

Oils, 83, 85

Olmesartan (Benicar), 245t, 267t

Omacor (omega-3-acid ethyl esters), 251t

Omega-3, 85

Omeprazole (Prilosec), 299
 combined with sodium bicarbonate (Zegerid), 300

OmniPod (insulin pump), 137, 174f, 175, 177f

OneTouch Ping (insulin pump), 176f

OneTouch Via (insulin pump), 174f, 177

Onglyza (saxagliptin), 118, 119f, 235
 combined with metformin (Kombiglyze XR), 123t

Online support/resources, 359-369, 419-426. *See also Internet.*

Onset of diabetes, age at, 23, 25t, 26

Oral agents for type 2 diabetes, 107-122. *See also Medications; Oral medications; specific medications and classes of medications.*
 adding to insulin, 133f, 135, 136
 algorithm for treatment, 132, 133f
 biguanides, 108, 112-114, 113t
 biguanides (metformin), 108, 112-114, 113t
 bile acid sequestrants, 108, 120-121, 121t
 carbohydrate absorption inhibitors, 108, 114-115, 114t

Oral agents for type 2 diabetes (*continued*)
 combination medications, 122, 123t, 130
 combination of medications, 133f, 134-135, 136
 dopamine receptor agonists, 108, 121-122, 122t
 DPP-4 inhibitors (incretin enhancers), 108, 118, 119f, 125, 235
 exercise-induced hypoglycemia and, 98-99
 general medication guidelines, 130-132, 132t
 hypoglycemia risk increased by some, 98-99, 235
 incretin mimetics, 123-130, 127t
 insulin secretagogues, nonsulfonylurea (Prandin, Starlix), 108, 111-112, 112t, 397-398
 insulin sensitizers (thiazolidinediones), 108, 115-117, 116t
 non-sulfonylurea insulin secretagogues, 108, 111-112, 112t
 pregnancy and, 108
 SGLT-2 inhibitors, 108, 118-120, 120t, 253
 sick-day rules, 64-65
 sulfonylureas (insulin secretagogues), 107, 108-111
 Oral glucose tolerance test (OGTT), 30-31, 30f, 399
 Oral hygiene, 313-315, 313t, 316. See also *Teeth and gums*.
 Oral medications, 107-122. See also *Oral agents for type 2 diabetes*.
 combination therapy. See *Combination therapy*.
 hypoglycemia risk and, 98-99, 235
 sick-day rules, 64-65
 Orinase (tolbutamide), 109t, 306
 exercise-induced hypoglycemia and, 98
 Orlistat (Xenical), 398, 398t, 401
 Oseni (alogliptin/pioglitazone), 123t
 Ospemifene (Osphena), 345
 Osteoarthritis, 294
 Osteoporosis, 294
 Overweight condition, 75t
 diabetes and, 31t, 401, 402t
 sleep apnea and, 325, 328, 328t

 Painful diabetic neuropathy (PDN), 282-283
 Pancreas, 297f, 304-305
 amylin from, 151
 antibody attacks on, 25, 25t
 artificial, 208, 406-407
 beta cells in, 25, 41, 124f, 226, 405
 destruction of cells, in type 1 diabetes, 24, 25t
 exhaustion of, 27, 110, 131
 exocrine impairment, 304-305
 normal function of, 24, 41, 139-140
 normal insulin production by, 124, 124f, 139-140
 normal insulin time course of action, 140-142, 143f
 pancreatic enzyme pills, 305
 Pantoprazole (Protonix). See *Protonix*.
 Participatory Medicine, 360
 Patient education, 18-19, 20-21. See also *Advocacy; Education*.
 being smart and persistent, 19, 21, 38
 empowered patient movement, 359-360
 PCSK9 inhibitors, 251-252, 251t
 Pentoxifylline, 322
 Pepcid (famotidine), 299
 Perindopril (Aceon), 245t, 266t

Periodontal disease, 309-311, 310f, 313
Periodontitis. See *Periodontal disease*.
Peripheral arterial disease, 100-101
Peripheral neuropathy, 100-101. See also *Neuropathy*.
 foot problems and, 279-281
Peristalsis, 124f, 125, 151
Pettus, Jeremy, 55, 70f, 137, 189, 397, 404, 417f
Pharmaceutical manufacturers, 424
Phenytoin (Dilantin), 301
Physical activity. See *Exercise*.
Pioglitazone (Actos), 115-117, 116t, 397
 ACT NOW study, 398t, 400
 in combination with alogliptin (Oseni), 123t
 in combination with glimepiride (Duetact), 123t
 in combination with metformin (Actoplus Met), 123t
Pitavastatin (Livalo), 268t
PKC beta (PKC B), 276
Plaque disease, 310
Polonsky, Bill, 20, 45, 53, 54f, 57f, 416
Portion sizes, 73, 74, 79, 88
Postmeal (postprandial) glucose value, 30, 30f, 36t
Potassium levels, high in blood, 266
Pramlintide (Symlin). See *Symlin*.
Prandimet (repaglinide/metformin), 123t
Prandin (repaglinide), 111-112, 112t
 combined with metformin (Prandimet), 123t
 exercise hypoglycemia risk and, 98-99
Pravachol (pravastatin), 251t, 268t
Pravastatin (Pravachol), 251t, 268t
“Prayer sign,” 289, 290f
Prazosin (Minipress), 245t
Precose (acarbose), 114-115, 114t, 115t, 397
 side effects of, 307
Prediabetes, 27, 29-30, 398-399, 402
 definition of, 398-399
 insulin resistance and, 27
 prevention of conversion to diabetes, 401
 as risk factor for type 2 diabetes, 401
 test values in, 29-30, 30f
Pregabalin (Lyrica), 282, 301
Pregnancy. See also *Gestational diabetes*.
 diabetes during, 28-29, 402t
 giving birth to 9-pound baby, 31, 31t, 402t
 glucose monitoring during (OGTT), 30-31
 medications to avoid during, 108, 266, 377
Prescription medications, 58, 62. See also *Insulin; Medications; Oral agents for type 2 diabetes*.
 safe and effective use of, 371-378
Prescription refills, 58
Prevacid (lansoprazole), 300
Prevention of diabetes, 397-408
 associated conditions and, 404
 case presentations, 407-408
 clinical trials on, 398t
 ACT NOW, 398t, 400
 DPP, 398t, 399-400, 403

Prevention of diabetes, clinical trial (*continued*)

- DREAM, 398t, 400
 - FDPS, 398t, 399, 403
 - NAVIGATOR, 401
 - ORIGIN, 398t, 401
 - STOP-NIDDM, 398t, 401
 - UKPDS, 35
 - XENDOS, 398t
 - insulin resistance and, 397-398
 - medications and, 404
 - prediabetes, 398-399, 401
 - research program, getting involved with, 404
 - risk factors for type 2 diabetes, 401-403, 402t
 - what to do about, 403-404
 - type 1 diabetes, 404-406, 407
 - type 2 diabetes, 397-404, 407-408
 - types of interventions, 397-398
- Prilosec (omeprazole), 299
- Prinivil (lisinopril), 245t, 266t
- Progesterone, 343-345
- Propranolol (Inderal/Inderal LA), 245t
- Propulsid (cisapride), 299
- Protein, 71, 81-86, 88
 - cheese and, 83, 84t
 - cholesterol in, 85
 - fat and, 81, 82-83, 82f
 - lean protein foods, 82
 - low-protein meal plan, 267
 - in urine. See *Microalbuminuria*.
- Pumping Insulin*, 174, 186
- Pumps (insulin), 171-187. See also *Insulin, pumps*.

Quality of life, 35, 90-91

- Questran (cholestyramine), 251t, 252
- Quinapril (Accupril), 245t, 266t

Ramipril (Altace), 245t, 266t, 374

- DREAM study, 398t, 400
- Ranitidine (Zantac), 299
- Rapid-acting insulins. See *Insulin, rapid-acting*.
- RealAge, 420
- Record keeping, 55-58. See also *Logbooks*.
 - diabetes history sheet, 58-59, 60f-61f
 - falsifying ("dry labbing"), 42, 43f
 - list of recommended tests, exams, and results, 55-57, 56f
 - medical record/history, 58-59, 60f-61f, 63
 - medications, 371-372
- Reflex sympathetic dystrophy (RSD), 292-293
- Reflux, esophageal, 298-299, 329-330
- Reglan (metoclopramide), 299
- Regular insulin, 141t, 143t, 144
- Relationships, 48-49, 53-54
 - doctor-patient, 42, 61-62
- Release-of-information form, 39
- Renal artery stenosis, 266

Renal disease. See *Kidney disease*.
Renin inhibitors, direct, 245t
Repaglinide (Prandin), 111-112, 112t
 combined with metformin (Prandimet), 123t
Research programs/trials, being involved in, 404, 405-406
Resources, 419-426
 calorie calculators, 73, 423
 diabetes resources, 419-424
 magazines and online resources, 421-422
 online, 359-369, 419-426
 organizations and associations, 419-421, 422-423, 426
 pharmaceutical manufacturers, 424
 travel, 425
Retina, 272-273. See also *Eye disease (diabetic retinopathy)*.
Retinal detachment, 102
Retinoid cream, 320, 322
Retinopathy. See *Eye disease (diabetic retinopathy)*.
Rezulin (troglitazone), 116, 398t
Rick Mendosa's Diabetes Directory, 422
Riding on Insulin, 420
Rifaximin (Xifaxan), 301
Riomet (metformin liquid), 113t
Risk factors for diabetes, 31t, 401-403, 402t
 Diabetes Risk Test, 402
Roberts, Ruth, 171
Rosenberg, Robert M., 317
Rosiglitazone (Avandia), 115-117, 116t, 397
 combined with glimepiride (Avandaryl), 123t
 combined with metformin (Avandamet), 123t
 DREAM study, 398t, 400
 safety of, 116
Rosuvastatin (Crestor), 251t, 252, 268t
Roszler, Janis, 349, 358
Ryzodeg 70/30, 142t

Saliva, 309
Salt in diet, 86, 87, 88
Sandostatin (octreotide), 304
Santos, Tricia, 107
Sama, 324
Satiety and appetite, 124f, 125, 151
Saturated fats, 87, 88
Saxagliptin (Onglyza), 118, 119f, 235
 combined with metformin (Kombiglyze XR), 123t
Saxenda, 126
Screening tests
 for diabetes, 26-27, 402t, 405, 408
 GAD, 26
 for gestational diabetes, 30-31
Secretagogues
 non-sulfonylurea insulin, 108, 111-112, 112t
 sulfonylureas (insulin secretagogues), 107, 108-111, 109t
Self-advocacy for diabetes patients. See *Advocacy*.
Self-management plan, 52-53
Semaglutide, 125, 126, 127t

Semmes Weinstein monofilaments, 281, 281f

Seneonics Eversense (continuous glucose monitor), 207-208

Sex hormone binding globulin (SHBG), 343

Sexual dysfunction

- causes of, 339-340
- counseling, 357
- diabetes and, 339-340
- estrogen/progesterone and, 343-345
- hormone treatment, 343-344
- hypoactive sexual desire disorder (HSDD), 342
- incidence of, in diabetics, 339
- low sexual desire, 340, 342
- in men, 339, 340, 345-347, 349-354
 - delayed ejaculation, 346-347
 - erectile dysfunction, 340, 345-346, 349-352
 - low testosterone, 352, 353f
 - premature ejaculation, 352-353
 - retrograde ejaculation, 340, 346
- treatments, 349-354
 - blood glucose control, 350
 - constriction rings, 350
 - herbs, 353-354
 - Kegel exercises, 353
 - Mediterranean Diet, 352
 - penile implants, 351
 - penile sleeves, 351
 - penile suppositories and injections, 351
 - pills, 350
 - vacuum pumps, 350-351
- relationships, focusing on, 356-357
- testosterone and, 342-343, 352, 353f
- in women, 339, 340, 341-345, 354-356
 - estradiol and progesterone, 343-345
 - lowered interest/arousal/orgasm, 341-345
 - menopause and, 343-344, 345
 - pain and vaginal dryness, 345, 355-356
 - painful sex, 345, 355-356
 - pelvic floor muscles and, 341-342
 - testosterone and, 342-343
- treatments
 - hormone treatments, 342-345
 - imagination, use of, 356
 - Kegel exercises, 356
 - pelvic floor physical therapy, 342
 - time and, 356
 - vaginal lubricants, 355
 - urinary tract infections, 354-355

Sexual health and function, 339-358. See also *Sexual dysfunction*.

- causes of sexual problems in diabetics, 339-340
- concerns in men with diabetes, 345-347, 349-354
- concerns in women with diabetes, 341-345, 354-356
- counseling and, 357
- embarrassment about discussing, 339
- glucose control and, 345, 350, 354

Sexual health and function (*continued*)
hormonal evaluation, 342-343
 estrogen and progesterone, 343-344
 sex hormone binding globulin (SHBG), 343
 testosterone, 342-343, 352, 353f
hypoglycemia risk (sex as exercise), 230
Kegel exercises for men, 353
Kegel exercises for women, 356
Mediterranean Diet and, 349, 352, 357-358, 358f
PAIRS seminar, 357
pelvic floor physical therapists, 342
relationships, focusing on, 356-357
Sex and Diabetes: For Him and For Her, 358
sex therapists, 341, 347, 349
sexual medicine, 339-347
specialized sexual medicine HCPs, 340-341, 347
Tantric sex, 349, 357
SFUs. See *Sulfonylureas (SFUs)*.
SGLT-2 inhibitors, 108, 118-120, 120t
 cardiovascular health and, 120, 253
 kidney health and, 263-264
 low hypoglycemia risk, 235
Shin spots (diabetic dermopathy), 321, 322f
Shoes, 103t, 392
Shoulders, 292-293
 frozen shoulder, 292
 shoulder-hand syndrome, 292-293
Sick-day rules, 64-65
Side effects, 306-307, 375
Simvastatin (Zocor), 251t, 252, 268t
 combined with ezetimibe (Vytorin), 251
Sitagliptin (Januvia), 118, 119f
 combined with metformin (Janumet), 123t
Skin, 317-324, 317t
 acanthosis nigricans, 320, 321f
 cancer, 322
 diabetic dermopathy (shin spots), 321, 322f
 eruptive xanthomas, 322, 324f
 as first line of defense, 317
 function of, 317
 fungus (warm moist areas), 319-320, 319f, 320f
 granuloma annulare, 320-321
 immune system and, 317-318
 itching, 323-324
 moisturizing for, 323-324
 necrobiosis lipoidica diabetorum (NLD), 321-322, 323f
 toenail fungus and athlete's foot, 318-319, 318f
Sleep, 325-338
 about, 326-327, 326f
 nocturia and, 329-330
 obstructive sleep apnea, 325-338
 about, 326-327, 326f
 bottom line, 337-338
 cardiovascular mortality and, 327, 327f, 337
 causes of, 326-327, 326f, 331

Sleep, obstructive sleep apnea (*continued*)
in children, 330
daytime sleepiness, 328-329, 331, 337
diagnosis, 331-332, 331f
esophageal reflux and, 329-330
high blood pressure and, 331
home sleep testing, 332
incidence (commonness) of, 325, 330
motor vehicle crashes and, 330, 337
overweight and obesity and, 325, 328, 328t, 331
screening questionnaire, 331, 331f
signs and symptoms of, 325, 327-330, 328t
sleep fragmentation, 330
sleep study, 327, 332
snoring and, 326, 328
thin woman, anatomy in, 329f
treating as a chronic disease, 334, 338
treatment of, 325-326, 332-338
bimaxillary advancement, 336, 337f
CPAP, 331, 332-334, 333f-335f, 333t
Inspire pacemaker, 337
mandibular advancement device, 334-336, 336f
mandibular osteotomy, 336, 337f
surgery, 336-337
tracheotomy, 336-337
uvulopalatopharyngoplasty, 336, 336f
undiagnosed, 331, 337
purpose of, 327
restless sleep, 329
sleep history, 331, 338
sleep study, 327, 332
unique to humans, 326-327
Sleep Health MD, 325-326
Small intestine, 301-303
Smoking, 239t, 241, 284, 313
avoiding, 241, 312, 313, 352
circulation problems and, 287
erectile dysfunction and, 352
heart disease risk and, 241
sex and, 340, 345, 352
sleep apnea and, 332
Snacks and snacking, 46, 139, 228-229
exercise and, 98, 104
Snoring, 326, 328
Social media, 359, 360-362
Diabetes Social Media Summit, 366
TCOYD on, 414
Sodium (salt), 86, 87, 88
Sodium bicarbonate/omeprazole (Zegerid), 300
Sodium-glucose co-transporter 2 inhibitors. *See SGLT-2 inhibitors.*
Soliqua (Lantus plus Adlyxin), 128, 129t, 155
Stable diabetes. *See Type 2 diabetes.*
Starlix (nateglinide), 111-112, 112t, 397-398
exercise hypoglycemia risk and, 98-99
Statins, 250-251, 251t, 252, 268, 268t

Stomach, 297f, 298-300
 delayed emptying (gastroparesis), 299-300
 GERD and, 298-299
 GLP-1 and, 124f, 125
 peristaltic contractions of, 124f, 125, 151
 ulcers, 300
 STOP-NIDDM Study, 398t, 401
 Stress, 49, 308
 Stroke. See also *Heart attack*.
 aspirin and, 253, 255
 attack, 237-255
 preventing, 237-255
 risk factors for, 238t, 239-241
 Sugar. See also *Glucose*.
 added sugars, 87
 carbohydrates and, 74
 dietary allowance of, 87
 sugar-free foods, 87
 Sulfonylureas (SFUs), 107, 108-111, 109t
 action mechanism of, 108
 adding another medication to, 110
 ADOPT trial, 109-110, 110f
 benefits and shortfalls of, 109-111, 110t
 for gestational diabetes, 29
 hypoglycemia and, 98, 111, 226, 235
 loss of effectiveness over time, 107, 109-110, 110f
 side effects of, 306-307
 specific agents, frequency, and dosages, 109t
 weight gain with, 110-111
 Support, 48-49, 53-54. See also *Internet*.
 Diabetes Etiquette Card for friends, 53-54
 online support, 359-369, 419-426
 support groups, 54
 unhelpful, 48-49, 54
 Survivorship concept, 359
 Sweets, always carrying for hypoglycemia, 65-66, 139
 Swelling. See *Edema*.
 Symlin (pramlintide, amylin), 137, 151-154, 299, 305
 benefits of, 153t
 initiation and titration schedule, 152-153, 154f
 side effects, 153
 tips for use, 153
 Symptoms of diabetes, 13, 30
 asymptomatic stage, 27, 408
 Synjardy (empagliflozin/metformin), 123t

 Taking Control Of Your Diabetes (TCOYD), 18-20, 411-416
 conferences, 18, 19, 411-412
 Dr. Edelman's Corner, 413
 The Edelman Report, 19, 411, 414
 education programs, 18-19, 20-21, 415-416
 Extreme Diabetes Makeover program, 19
 health fairs, 411-412
 Making the Connection programs, 19-20, 415-416
 mission statement, 20, 411

Taking Control Of Your Diabetes (TCOYD) (*continued*)
“never too late” philosophy, 20, 409-418
newsletter, 413-414
social media and, 414
themes of, 18-19, 20
vision for, 416-417
web site (www.tcoyd.org), 364, 411, 422
Tandem t:slim pump, 172f, 174f, 176f
in combination with CGM, 191f
Tantric sex, 349, 357
Tanzeum (albiglutide), 125-128, 127t, 235
side effects, 307
Taste sensation, decrease in, 312
TCOYD. See *Taking Control of Your Diabetes*.
TeamType 1, 421
Technosphere Insulin. See *Afrezza*.
TEDDY (The Environmental Determinates of Diabetes in the Young), 405
Teeth and gums, 309-316
bad breath (halitosis), 312
blood glucose control and, 313
brushing and flossing, 313-314, 314f
case presentation, 316
complications and diseases, 36t
dental examination, 315-316
precautions for, 315, 315t
questions your dentist may ask, 315-316
dentures, 314
diabetes effect on, 309
diet and, 313
dry mouth, 311, 311t
mouthwashes, 314
oral fungal infection (candidiasis), 311-312
oral hygiene, 313-315, 313t, 316
oral neuropathy, 312
periodontal disease, 309-311, 310t, 313
taste sensation, decreased, 312
teeth cleaning, 314-315
wound healing, delayed, 312
Tegretol (carbamazepine), 301
Tekturna (aliskiren), 245t, 246
Telmisartan (Micardis), 245t, 267t
Tenderich, Amy, 359
Tendons. See *Joints*.
TENS (transcutaneous nerve stimulation), 283
Terazosin (Hytrin), 245t
Testosterone, 342-343, 352, 353f
Tests, 29-31, 29t, 30f. See also *Numbers/levels*.
for diabetes diagnosis, 29-31, 29t, 30f
follow-up, 62
frequency of, 52, 55, 63
list of, 55, 56f
list of recommended tests, exams, and results, 55-57, 56f
prediabetic values in, 29-30, 30f
results
discouraging, dealing with, 49-50

Tests, results (*continued*)
 dry labbing, 42, 43f
 need to know numbers in, 38, 51-52, 62
 release-of-information form for, 39
 requesting, 38
 Teveten (eprosartan), 245t, 267t
 Thiazide diuretics, 245t, 247
 Thiazolidinediones (TZDs), 115-117, 116t
 benefits and shortfalls of, 116-117, 117t
 hypoglycemia risk, 235
 safety of, 116
 side effects of, 117, 117t
 Thirst, excessive, 13, 30
 Throat, 298-299
 Time course of action (of insulins), 140-142, 141t-142t, 143f
 Toenail fungus, 286, 318-319, 318f
 Tolazamide (Tolinase), 109t
 Tolbutamide (Orinase), 109t, 306
 Tolinase (tolazamide), 109t
 Tornambe, Paul E., 271, 277-278, 278f
 Toujeo, 137, 141t, 143f, 147, 148
 initiating, 165t
 Tradjenta (linagliptin), 118, 119f
 combined with metformin (Jentadueto), 123t
 Trandolapril (Mavik), 245t, 266t
 Travel, 372, 389-396
 adjusting insulin therapy during, 394-396
 airport security/TSA rules, 393-394
 carry-on luggage, 391-392
 diet and, 392-393
 glucose tabs or sources, 392
 insulin pumps, 389, 391, 393, 394
 insulin use in airplanes, 393
 list of medications, 372
 medications and supplies
 carry-on luggage, 391-392
 overseas, 390-391
 protection for, 391-392
 radiation exposure, 394
 taking twice as many as needed, 390
 temperature concerns, 391-392
 online resources, 425
 packing for, 389-390, 390t
 physician letter for, 389, 390t
 pre-travel planning, 389-390, 390t
 radiation exposure, 394
 shoes, 392
 taking breaks, 392
 time zones, insulin doses and, 394-396
 travel insurance and safety, 393, 425
 units and dosages for foreign travel, 390-391
 vaccinations, 391, 425
 what qualifies as, 389

Treatment for diabetes. See also *Diet; Exercise; Medications; and specific agents and classes of agents.*

- algorithm for, 132, 133f
 - insulin therapy, 156-159, 158f
- being be up-to-date on, 19, 107-108, 135-136, 411
- cornerstones of (diet, exercise, medications), 131-132, 132t, 409
- early, 27, 107, 132t, 136, 408
- essential components, 409
- gestational diabetes, 29
- GLP-1 analogues, 154-155, 235
- guidelines for, 130-132, 132t
- individualization of, 31
- insulin therapy, 137-170
 - algorithms for, 156-159, 158f
- need to know about, 107-108, 135-136, 411
- oral agents for type 2 diabetes, 107-122
- self-education about, 18-19, 20-21
- type 1, 24-25, 25t
 - future treatments, 26
 - insulin therapy, 137-170
 - oral medications not approved for, 108
- type 2, 25t, 27, 132, 133f
 - glucose-lowering medications, 107-136
 - insulin therapy, 137-170
 - oral agents, 107, 108-122
- Trend arrows (continuous glucose monitors), 190, 192f, 195-198
- Trend lines (insulin pumps), 172
- Tresiba (insulin degludec), 104, 141t, 143f, 147, 148, 150
 - combined with Victoza (Xultophy), 128, 128t, 155
 - initiating, 165t
- TrialNet, 405-406, 426
- Tricor (fenofibrate), 251t, 252
- Tricyclic antidepressants (TCAs), 282, 301
- Trigger finger, 290, 291f, 292f, 295
 - surgery for, 295, 295f
- Triglycerides, 248
 - controlling, 116, 251t, 252
 - elevated, 250
 - goal, 248t
- Trilipix (fenofibric acid), 251t, 252
- Troglitazone (Rezulin), 116, 398t, 400
- Trowbridge, Janet M., 317
- Trulicity (dulaglutide), 126, 127, 127t, 235
 - side effects, 307
- T:slim pump, 172f, 174f, 176f
- TuDiabetes.org*, 364
- Twin studies, 405
- Twitter, 359, 361, 367
 - diabetes hashtags, 367t
- Tylenol-containing medications, 199, 206, 223, 374
- Type 1 diabetes, 23-26
 - age at onset, 23, 25t
 - body weight in, 23, 25t
 - cause of, 24, 405
 - frequency in US population, 24, 25t

Type 1 diabetes (*continued*)
genetics and, lack of heritability, 24
hypoglycemia and, 225, 228-234
insulin deficiency in, 24
insulin therapy, 140, 168-170, 170t
LADA as subgroup of, 25-26
new classification for, 406
online groups, 420, 421
other names for, 23, 24t
prevention, 404-406
 artificial pancreas and, 406-407
stages 1, 2, 3, 406
treatment for, 24-25, 25t. See also *Diet; Exercise; Insulin*.
 basal/bolus insulin, 140
 future treatments, 26
 oral medications not recommended, 108
type 2 diabetes compared with, 25t

Type 2 diabetes, 26-27
age at onset, 25t, 26
associated conditions, 25t, 31t, 404
body weight and, 25t, 26
causes of, 25t, 27
diagnosis of, 29-31
 early, importance of, 27, 136, 408
 years for, 27
early stages, lack of symptoms in, 27, 408
ethnicity and, 25t, 26, 31t, 401
family history of, 24, 26, 401, 402t
frequency in US population, 25t
genetics of, 25t, 26, 47-48
heritability of, 24, 26, 47-50
hypoglycemia and, 225-226, 234-236
insulin resistance in, 27, 28f, 108-109
natural history of, 27, 28f, 131, 138
other names for, 24t, 26
percentage of US population having, 24
prevention of, 397-404
risk factors for, 31t, 401-403, 402t
screening for, 27, 402t, 408
treatment for, 25t, 27. See also *Diet; Exercise; specific treatment agents*.
 insulin, 137-170, 170t
 oral agents and incretins, 107-122
type 1 diabetes compared with, 25t

TZDs. See *Thiazolidinediones (TZDs)*.

U-100 (Admelog, insulin lispro), 141t, 143, 144t
U-200 insulin lispro, 141t, 150
U-300 (Toujeo, insulin glargine), 141t, 143f, 147, 148, 165t
U-500 (Humalog, insulin lispro), 141t, 150

Ulcers
 foot, 100-101, 280, 283-284, 286, 290
 stomach, 300

Unconsciousness (from hypoglycemia), 65, 227, 232
United Kingdom Prospective Diabetes Study (UKPDS), 35
Univasc (moexipril), 245t, 266t

Unstable diabetes. See *Type 1 diabetes*.

Urea, 318, 320

Urinary albumin-to-creatinine ratio (UACR), 260-261

Urinary tract infections, 30, 36t, 354-355

Urination

- excessive, 13, 36t
- night time (nocturia), 329-330

Urine

- protein in (microalbuminuria), 259-262, 260t
- testing, 39, 39f, 189
 - inaccuracy of, 39

Uvulopalatopharyngoplasty (UPPP), 336, 336f

V-Go (insulin pump), 177, 177f

Vaccinations, 391, 425

Vaginal atrophy/dryness, 345, 355-356

Vaginal infections, 36t, 300

Valsartan (Diovan), 245t, 267t

Vascular disease, 283-284

Vascular endothelial growth factor. See *VEGF*.

Vasotec (enalapril), 245t, 266t

Vegetables, 71, 76t, 77t, 78, 81, 88

VEGF (vascular endothelial growth factor), 273, 275

- inhibitors, 275, 276f, 277

Verapamil, 245t

Viagra, 350, 352

Vibe G4 (insulin pump), 176f

- CGM-enabled, 191f

Victoza (liraglutide), 126-127, 127t, 299, 305

- heart benefits of, 254
- high-dose (Saxenda), 126
- low hypoglycemia risk, 235
- side effects of, 307

Viruses, 24, 405

Vision. See *Eye; Eye disease*.

Vitamins, 87

- B12, 281, 404
- D, 294, 405
- E, 305

Vitrectomy, 273, 275

Vytorin (ezetimibe/simvastatin), 251, 251t

Walking, 94-95

Walsh, John, 171

Warranty program, diabetes, 55-57, 56f, 59, 410

Web sites, 419-426

- highly recommended, 368t
- pharmaceutical manufacturers, 424
- TCOYD (www.tcoyd.org), 364, 411, 422

Weight, 73-74, 75t, 241, 403

- BMI and, 73-74, 75t
- calories/day and, 72
- diabetes risk and, 31t, 401, 402t
- exercise and, 83-84

Weight (*continued*)

- gain, 35, 72
 - as medication side effect, 110-111, 112, 117
- ideal, 75t, 403
- loss, 72, 397
 - GLP-1 analogues and, 154-155
 - incretin mimetics and, 126, 132t
 - Victoza/Saxenda and, 126
- obesity, 75t
 - central, 31t, 402t
- type 1 diabetes patients, 23, 25t
- type 2 diabetes patients, 25t, 26
- Welchol (colesevelam), 120-121, 121t, 251t, 252
- Werewolf syndrome, 46
- Wolosin, James D., 297
- Workplace, 379-388, 423
 - advantages of diabetes in (and letting people know), 387
 - attitude, 385
 - “disability” and, 381, 385, 386, 423
 - employment behavior and work issues, 382-383
 - federal laws on, 381
 - food in, 384, 385
 - health exams for, 380
 - hiding diabetes, 380
 - Job Accommodation Network, 423
 - job interviews, 386
 - key to success in, 381-383
 - launching a business, 383, 385-386, 388
 - legal issues in, 386
 - military, 379-380, 388
 - Miyares, Urban, contact information, 385, 388
 - new career directions, 383
 - recent diabetes diagnosis and, 383
 - tips for diabetes health in, 384-386
 - uncontrolled diabetes and, 381, 383, 387-388
 - web sites, 388, 423
- Wounds/wound care, 280, 286, 287, 312
 - poor wound healing, 13, 30, 36t, 280

Xanthomas, eruptive, 322, 324f

XENDOS Study, 398t, 401

Xenical (orlistat), 398, 398t, 401

Xerostomia (dry mouth), 311, 311t

Xifaxan (rifaximin), 301

Xigduo (dapagliflozin/metformin ER), 123t

Xultophy (Tresiba and Victoza), 128, 128t, 155

Yeast infections, 300, 319-320, 320f

Zantac (ranitidine), 299

Zeasorb/Zeasorb-AF, 319

Zegerid (omeprazole/sodium bicarbonate), 300

Zestril (lisinopril), 245t, 266t

Zetia (ezetimibe), 250-251, 251t

Zocor (simvastatin), 251t, 252, 268t